Fact CheckerSign in

NCT07818473Not yet recruiting

Conventional vs Biologic Therapy in Pediatric IBD

Effectiveness, Safety, and Adverse Events of Conventional and Biologic Therapy in Pediatric Inflammatory Bowel Disease

Source: ClinicalTrials.gov · Last updated 14 Sept 2026

Brief summary (registry, in English)

This combined retrospective-prospective cohort study aims to evaluate the effectiveness, safety, and adverse events of conventional versus biologic therapy in children and adolescents with inflammatory bowel disease at Assiut University Children Hospital.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
8 Sept 2026
Start date
10 Sept 2026
Primary completion date
10 Sept 2027
Lead sponsor
Assiut University
NCT number
NCT07818473

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 10 Sept 2026 to the primary completion date, 10 Sept 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • Age more than 18 years

Other

  • \- Incomplete medical records precluding assessment of primary endpoints
  • Discontinuation of follow-up before a minimum evaluable treatment period

Who the study is looking for

  • \- Confirmed diagnosis of Crohn's disease, ulcerative colitis, or IBD-unclassified according to revised Porto criteria
  • Age at diagnosis less than 18 years
  • Receipt of conventional therapy and/or biologic therapy for a minimum evaluable treatment duration
  • Availability of adequate medical records
  • Written informed consent (for prospective component)

Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.